Source: Healio.com
April 03, 2021
2 min read
Save

7 recent reports in IBD

Source: Healio.com
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio Gastroenterology presents the following reports on the most recent research on inflammatory bowel disease.

These reports include new research on the impact of greenspace exposure, gluten intake and yeast commonly found in cheese.

Gluten intake not linked with IBD risk

Dietary gluten intake was not associated with risk for Crohn’s disease or ulcerative colitis, according to study results.

Hamed Khalili, MD, MPH, from Massachusetts General Hospital, and colleagues wrote that patients with inflammatory bowel disease often report improvements in symptoms after restricting their gluten intake. READ MORE

Q&A: Yeast common in cheese, processed meats impairs healing in Crohn’s

Researchers from Cleveland Clinic found an infection that prevents healing in patients with Crohn’s disease, according to study results published in Science.

Healio Gastroenterology spoke with Thaddeus Stappenbeck, MD, PhD, chair inflammation and immunity at Cleveland Clinic, about results from the study that examined the yeast Debaryomyces hansenii. Investigators found higher levels of the yeast among patients with Crohn’s disease. The results showed D. hansenii was abundant in inflamed regions of the colon and small intestine, which may be a sign of unhealed intestinal wounds. READ MORE

New understanding of monogenic IBD may lead to effective management

Monogenic inflammatory bowel disease, while rare, has varied extra-intestinal comorbidities and limited treatments, according to a study published in Clinical Gastroenterology and Hepatology.

“In recent years, the number of novel genes causing monogenic IBD has been increasing, but in parallel with these discoveries, there is an urgent need to better understand this group of diseases to enable prompt diagnosis, improve prognosis, predict the clinical course and to establish new treatment strategies,” Ryusuke Nambu, MD, from the SickKids Inflammatory Bowel Disease Centre, the Hospital for Sick Children in Toronto, Canada, and colleagues wrote. “From this systematic review, we now have an improved understanding of the underlying genetic basis of these diseases, especially those with relatively high frequencies, paving the way for prognostication and effective management.” READ MORE

Mirikizumab helps patients with UC achieve clinical remission

Lilly announced mirikizumab for treatment of ulcerative colitis met primary and secondary endpoints in the LUCENT-1 12-week, phase 3 induction study, according to a press release.

LUCENT-1 assessed the efficacy and safety of mirikizumab for treatment of patients with moderate-to-severe UC. READ MORE

Xeljanz effective for UC regardless of prior TNFi failure

Regardless of prior tumor necrosis factor inhibitor failure status, Xeljanz was efficacious in patients with ulcerative colitis, according to a study published in Clinical Gastroenterology and Hepatology.

“Prior TNFi failure has been suggested as a predictor of poor prognosis, and patients who have previously failed TNFi therapy may be more difficult to treat than those who have not,” William J. Sandborn, MD, from the division of gastroenterology at the University of California, San Diego, and colleagues wrote. “Therefore, there is an unmet need for alternative therapies in patients with prior TNFi failure.” READ MORE

Subcutaneous Remsima non-inferior to IV formulation

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

Byong Duk Ye, MD, PhD, from the department of gastroenterology and IBD center at University of Ulsan College of Medicine in South Korea, and colleagues wrote that the IV formulation of Remsima (CT-P13 IV, Celltrion) has an established role in the treatment of IBD, but a subcutaneous version (CT-P13 SC) has several potential benefits. READ MORE

Greenspace exposure during childhood reduces risk for IBD

Childhood exposure to residential greenspace was associated with a reduced risk for inflammatory bowel disease, according to data published in the American Journal of Gastroenterology.

Intervention studies designed to target specific environmental risk factors to reduce the risk of IBD should include greenspace in study design,” Michael Elten, MSc, from the School of Epidemiology and Public Health, University of Ottawa in Canada, and colleagues wrote. “It is possible that by changing our immediate environment, we could prevent childhood-onset IBD.” READ MORE